BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 19995789)

  • 1. Tumor multiplicity is an independent prognostic factor of non-muscle-invasive high-grade (T1G3) bladder cancer.
    Nakai Y; Nonomura N; Kawashima A; Mukai M; Nagahara A; Nakayama M; Takayama H; Nishimura K; Okuyama A
    Jpn J Clin Oncol; 2010 Mar; 40(3):252-7. PubMed ID: 19995789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors.
    Alkhateeb SS; Van Rhijn BW; Finelli A; van der Kwast T; Evans A; Hanna S; Vajpeyi R; Fleshner NE; Jewett MA; Zlotta AR
    J Urol; 2010 Jul; 184(1):81-6. PubMed ID: 20478593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is T1G3 bladder cancer having a definite muscle layer in TUR specimens a highly progressive disease?
    Shindo T; Masumori N; Fukuta F; Miyamoto S; Tsukamoto T
    Jpn J Clin Oncol; 2010 Feb; 40(2):153-6. PubMed ID: 19841100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
    Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
    Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor multiplicity is an independent prognostic factor of non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin immunotherapy.
    Ajili F; Manai M; Darouiche A; Chebil M; Boubaker S
    Ultrastruct Pathol; 2012 Oct; 36(5):320-4. PubMed ID: 23025650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years.
    Serretta V; Pavone C; Ingargiola GB; Daricello G; Allegro R; Pavone-Macaluso M
    Eur Urol; 2004 Jun; 45(6):730-5; discussion 735-6. PubMed ID: 15149744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials.
    Fernandez-Gomez J; Solsona E; Unda M; Martinez-Piñeiro L; Gonzalez M; Hernandez R; Madero R; Ojea A; Pertusa C; Rodriguez-Molina J; Camacho JE; Isorna S; Rabadan M; Astobieta A; Montesinos M; Muntañola P; Gimeno A; Blas M; Martinez-Piñeiro JA;
    Eur Urol; 2008 May; 53(5):992-1001. PubMed ID: 17950987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.
    Uchida A; Yonou H; Hayashi E; Iha K; Oda M; Miyazato M; Oshiro Y; Hokama S; Sugaya K; Ogawa Y
    Urology; 2007 Feb; 69(2):275-9. PubMed ID: 17320663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
    Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K; Chihara Y; Kondo H; Hirao Y
    Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?
    Park J; Song C; Shin E; Hong JH; Kim CS; Ahn H
    Urol Oncol; 2013 Aug; 31(6):849-56. PubMed ID: 21782482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of gender on response to bacillus Calmette-Guérin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder.
    Boorjian SA; Zhu F; Herr HW
    BJU Int; 2010 Aug; 106(3):357-61. PubMed ID: 20002665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience.
    Iida S; Kondo T; Kobayashi H; Hashimoto Y; Goya N; Tanabe K
    Int J Urol; 2009 Mar; 16(3):287-92. PubMed ID: 19207115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retinoblastoma protein expression predicts response to bacillus Calmette-Guérin immunotherapy in patients with T1G3 bladder cancer.
    Cormio L; Tolve I; Annese P; Saracino A; Zamparese R; Sanguedolce F; Bufo P; Battaglia M; Selvaggi FP; Carrieri G
    Urol Oncol; 2010; 28(3):285-9. PubMed ID: 18976938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
    Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
    Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
    Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM
    J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.